EMA

Stamp of approval
#CHMP #EMA #Marketing approval authorisation #Regulatory

The CHMP recommends 14 new medicines for approval

The EU’s Committee for Medicinal Products for Human Use (CHMP) recommended granting a marketing authorisation for 14 new medicines in its July meeting. The following novel medicines and biosimilars each received a positive opinion: Abrysvo (bivalent, recombinant), a vaccine to protect small infants… Read More

#News #Regulatory

AI brain
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #EMA #Machine learning

EMA urges “human-centric approach” to AI in drug discovery

The European Medicines Association (EMA) has published a draft reflection paper outlining the current thinking on the use of artificial intelligence (AI) to support the safe and effective development, regulation and use of medicines. The paper, which is now open for public consultation, reflects on principles… Read More

#News #Regulatory

Monoclonal antibodies
#Astellas Pharma #Cancer research #EMA #Gastrointestinal #Monoclonal antibodies #Oncology

EMA reviews monoclonal antibody for gastric cancer

The European Medicines Agency (EMA) has accepted for regulatory review Astellas Pharma’s marketing authorisation application (MAA) for zolbetuximab, an investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody. The application is for authorisation as a first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal… Read More

#News #Regulatory

Doctor writing a prescription
#Drug repurposing #EMA #FDA #MHRA #Regulatory #Unlicensed drug

Unlicensed and off-label drugs: What do we know?

Following the death of a cancer patient after they were given an unlicensed drug, Diana Spencer unpacks the practice of prescribing unlicensed and off-label medicines. This month, a cancer patient died and three others were hospitalised in the UK after they were administered… Read More

#Exclusive Content #Regulatory

Ozempic box
#Adverse event #Diabetes #Drug safety #EMA #Type 2 diabetes

EMA reviews drug data relating to suicide risk

The European Medicines Agency (EMA) safety committee, the Pharmacovigilance Risk Assessment Committee (PRAC), is reviewing data on the risk of suicidal thoughts and thoughts of self-harm related to GLP-1 receptor agonists. The drugs under review include Ozempic (semaglutide), Saxenda (liraglutide) and Wegovy (semaglutide), used for weight… Read More

#News

Pills
#EMA #Europe #Hypertension #Janssen #Phase III trial

Janssen seeks EMA approval for hypertension combination therapy

Janssen has submitted a marketing authorisation application to the European Medicines Agency (EMA) seeking approval of single tablet combination therapy (STCT) of macitentan and tadalafil for pulmonary arterial hypertension (PAH). The single tablet combination therapy of macitentan 10mg and tadalafil 40mg (M/T STCT) is intended for… Read More

#News #Regulatory

Gene therapy
#AAV #EMA #Gene therapy #Genethon #Genetic diseases #Liver disease #Priority Review

Gene therapy for rare liver disease gets EMA priority status

The European Medicines Agency (EMA) has granted PRIME (Priority Medicines) status to the gene therapy, GNT-0003, currently in clinical trials for Crigler-Najjar syndrome, a rare liver disease.   This status, granted only to drug candidates with major therapeutic potential, follows the successful completion of the first phases of… Read More

#Editor's Choice #News #Regulatory

#AI / data analytics / healthtech / informatics #Digital solutions #Digital workflow #EMA #FDA #Regulatory

Quicker time to regulatory submission through improved data management

Listen to this article on the DDW Podcast: Robust digital workflows can reduce errors and time to compile data leading to greater transparency, faster reporting and help biopharmaceutical companies reach regulatory submission faster. Ken Forman, Senior Director of Product Strategy, IDBS explains. For many start-ups operating on… Read More

#Exclusive Content

#CHMP #EMA #Ipsen #Marketing approval authorisation #Phase III trial #Regulatory

CHMP rejects rare bone disease treatment in EU

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended not to grant marketing authorisation for Ipsen’s investigational palovarotene as a treatment for fibrodysplasia ossificans progressiva (FOP).   The company says it will be requesting a re-examination of the CHMP opinion,… Read More

#News #Regulatory

#AI / data analytics / healthtech / informatics #Data management #Data standardisation #EMA #FDA #Regulatory #Trial data

Driving enhanced patient outcomes through data standardisation 

Greater data-centricity, supported by new technologies, is key to driving efficient product approvals and supply chains. Frits Stulp and Aida Demneri, partners at Deloitte (including Iperion – a Deloitte business), outline how life sciences companies can play their part in driving change. In the past two years, EU… Read More

#Exclusive Content

#Drug discovery #EMA #Funding #Huntington's disease #Monkeypox #Start-ups

This week in drug discovery (21 – 25 August)

News round-up for 21-25 August by DDW Editor Reece Armstrong A treatment for Monkeypox, spider venom for drug discovery and funding for international start-ups are some of the stories in this week’s news round-up. Covid researchers launch Monkeypox study   A new study investigating a potential treatment… Read More

#News

EMA concept
#Clinical trials #EMA #Oncology #Regulatory

Combination treatment for AML closer to approval following EMA nod

The European Medicines Agency (EMA) has granted a Marketing Authorisation Application (MAA) for a combination treatment targeting adults with acute myeloid leukaemia (AML) who are not candidates for standard induction chemotherapy.  The MMA was granted to Otsuka Pharmaceutical and Astex Pharmaceuticals’ oral fixed-dose combination of decitabine and… Read More

#Cancer Research #News #Regulatory

#Appointment #Covid-19 #EMA #MHRA #Oncology

This week in drug discovery (15-19 August)

News round-up by DDW Editor Reece Armstrong for 15-19 August. Covid booster approvals, positive results for Malaria vaccines and new CEOs are some of the stories in this week’s news round-up.  MHRA approves Moderna’s bivalent Covid booster   The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an updated… Read More

#News

Human brain
#Biopharma #Cell and gene therapy #EMA #Rare disease

Gene therapy for rare brain disease gets nod from EMA

A gene therapy targeting a rare brain disorder has received a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). PTC Therapeutics’ one-time gene replacement therapy Upstaza was given a positive opinion for the treatment for aromatic L-amino acid decarboxylase (AADC)… Read More

#News

#Data #EMA #Regulatory

What an EMA decision means for data-based regulatory submissions

The European Medicines Agency (EMA) has confirmed that the UNICOM’s DADI (Digital Application Dataset Integration) project will now serve as a ‘Plan B’ for the implementation of regulatory data submissions. Amplexor’s Renato Rjavec looks at the opportunities and challenges this presents for pharma companies. A more data-driven way of managing… Read More

#Exclusive Content #Opinion #Regulatory

#Covid-19 #EMA #FDA #Immunology / Virology & Vaccines #Pfizer

Pfizer and BioNTech submit data for the vaccination of children 5 to 12 years 

Pfizer and BioNTech have submitted data supporting the vaccination of children 5 to 12 years of age with Comirnaty (Covid-19 mRNA vaccine) to the European Medicines Agency (EMA) for a variation of the Conditional Marketing Authorization (CMA) in the European Union (EU). According to The New York Times, federal regulators evaluated the… Read More

#News